190 related articles for article (PubMed ID: 19627758)
21. [Calcimimetics: physiology, results of preclinical and clinical studies, and perspectives].
Torres PU
Nephrol Ther; 2011 Apr; 7(2):99-104. PubMed ID: 21310676
[TBL] [Abstract][Full Text] [Related]
22. Medical management of primary hyperparathyroidism.
Khan AA
J Clin Densitom; 2013; 16(1):60-3. PubMed ID: 23374743
[TBL] [Abstract][Full Text] [Related]
23. Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.
Imanishi Y; Kawata T; Kenko T; Wada M; Nagano N; Miki T; Arnold A; Inaba M
Calcif Tissue Int; 2011 Jul; 89(1):29-35. PubMed ID: 21541686
[TBL] [Abstract][Full Text] [Related]
24. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.
Kawata T; Imanishi Y; Kobayashi K; Onoda N; Okuno S; Takemoto Y; Komo T; Tahara H; Wada M; Nagano N; Ishimura E; Miki T; Ishikawa T; Inaba M; Nishizawa Y
J Bone Miner Metab; 2006; 24(4):300-6. PubMed ID: 16816924
[TBL] [Abstract][Full Text] [Related]
25. [Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].
Nagano N
Clin Calcium; 2005 Jan; 15(1):71-8. PubMed ID: 15632475
[TBL] [Abstract][Full Text] [Related]
26. Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis.
Akinci B; Comlekci A; Tankurt E
Exp Clin Endocrinol Diabetes; 2009 Mar; 117(3):142-5. PubMed ID: 18561096
[TBL] [Abstract][Full Text] [Related]
27. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
[TBL] [Abstract][Full Text] [Related]
28. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.
Iglesias P; Ais G; González A; Tajada P; García Arévalo C; Fernández Pardo E; Díez JJ
Am J Med Sci; 2008 Feb; 335(2):111-4. PubMed ID: 18277118
[TBL] [Abstract][Full Text] [Related]
29. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling.
Cetani F; Saponaro F; Banti C; Cianferotti L; Vignali E; Chiavistelli S; Viccica G; Pinchera A; Marcocci C
J Endocrinol Invest; 2012 Jul; 35(7):655-60. PubMed ID: 21971564
[TBL] [Abstract][Full Text] [Related]
30. [Clinical application of calcimimetics].
Nishi H; Fukagawa M
Clin Calcium; 2004 May; 14(5):756-9. PubMed ID: 15577038
[TBL] [Abstract][Full Text] [Related]
31. Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study.
Brardi S; Cevenini G; Verdacchi T; Romano G; Ponchietti R
Arch Ital Urol Androl; 2015 Mar; 87(1):66-71. PubMed ID: 25847900
[TBL] [Abstract][Full Text] [Related]
32. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.
Peacock M; Bilezikian JP; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
J Clin Endocrinol Metab; 2011 Jan; 96(1):E9-18. PubMed ID: 20943783
[TBL] [Abstract][Full Text] [Related]
33. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.
Khan A; Bilezikian J; Bone H; Gurevich A; Lakatos P; Misiorowski W; Rozhinskaya L; Trotman ML; Tóth M
Eur J Endocrinol; 2015 May; 172(5):527-35. PubMed ID: 25637076
[TBL] [Abstract][Full Text] [Related]
34. Primary hyperparathyroidism.
Muñoz-Torres M; García-Martín A
Med Clin (Barc); 2018 Mar; 150(6):226-232. PubMed ID: 28992983
[TBL] [Abstract][Full Text] [Related]
35. Cinacalcet for the treatment of primary hyperparathyroidism.
Sajid-Crockett S; Singer FR; Hershman JM
Metabolism; 2008 Apr; 57(4):517-21. PubMed ID: 18328354
[TBL] [Abstract][Full Text] [Related]
36. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1).
Giusti F; Cianferotti L; Gronchi G; Cioppi F; Masi L; Faggiano A; Colao A; Ferolla P; Brandi ML
Endocrine; 2016 Jun; 52(3):495-506. PubMed ID: 26224587
[TBL] [Abstract][Full Text] [Related]
37. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis.
Brunaud L; Ngueyon Sime W; Filipozzi P; Nomine-Criqui C; Aronova A; Zarnegar R; Kessler M; Frimat L; Ayav C
Surgery; 2016 Jan; 159(1):183-91. PubMed ID: 26476826
[TBL] [Abstract][Full Text] [Related]
38. Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature.
Vera L; Oddo S; Di Iorgi N; Bentivoglio G; Giusti M
J Med Case Rep; 2016 Dec; 10(1):361. PubMed ID: 27998296
[TBL] [Abstract][Full Text] [Related]
39. The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies.
Chandran M; Bilezikian JP; Lau J; Rajeev R; Yang SP; Samuel M; Parameswaran R
Rev Endocr Metab Disord; 2022 Jun; 23(3):485-501. PubMed ID: 35041148
[TBL] [Abstract][Full Text] [Related]
40. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.
Peacock M; Bilezikian JP; Klassen PS; Guo MD; Turner SA; Shoback D
J Clin Endocrinol Metab; 2005 Jan; 90(1):135-41. PubMed ID: 15522938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
